Yanis A. Boumber, Ph.D.
Affiliations: | 2005 | The University of Texas Graduate School of Biomedical Sciences at Houston |
Area:
Molecular BiologyGoogle:
"Yanis Boumber"Parents
Sign in to add mentorJean-Pierre Issa | grad student | 2005 | The University of Texas Graduate School of Biomedical Sciences at Houston | |
(An Sp1/Sp3 site polymorphism associated with hypermethylation of the candidate tumor suppressor gene RIL in cancer.) |
BETA: Related publications
See more...
Publications
You can help our author matching system! If you notice any publications incorrectly attributed to this author, please sign in and mark matches as correct or incorrect. |
Topchu I, Bychkov I, Gursel D, et al. (2023) NSD1 supports cell growth and regulates autophagy in HPV-negative head and neck squamous cell carcinoma. Biorxiv : the Preprint Server For Biology |
Bychkov I, Deneka A, Topchu I, et al. (2023) Musashi-2 (MSI2) regulation of DNA damage response in lung cancer. Biorxiv : the Preprint Server For Biology |
Bychkov I, Topchu I, Makhov P, et al. (2023) Regulation of VEGFR2 and AKT Signaling by Musashi-2 in Lung Cancer. Cancers. 15 |
Bychkov I, Topchu I, Makhov P, et al. (2023) Regulation of VEGFR2 and AKT signaling by Musashi-2 in lung cancer. Biorxiv : the Preprint Server For Biology |
Khaddour K, Felipe Fernandez M, Khabibov M, et al. (2022) The Prognostic and Therapeutic Potential of DNA Damage Repair Pathway Alterations and Homologous Recombination Deficiency in Lung Cancer. Cancers. 14 |
Topchu I, Pangeni RP, Bychkov I, et al. (2022) The role of NSD1, NSD2, and NSD3 histone methyltransferases in solid tumors. Cellular and Molecular Life Sciences : Cmls. 79: 285 |
Topchu I, Karnaukhov N, Mazitova A, et al. (2021) Musashi 2 (MSI2) expression as an independent prognostic biomarker in non-small cell lung cancer (NSCLC). Journal of Thoracic Disease. 13: 1370-1379 |
Deneka A, Kharin L, Karnaukhov NS, et al. (2020) Musashi 2 (MSI2) expression as an independent prognostic biomarker in non-small cell lung cancer (NSCLC). Journal of Clinical Oncology. 38 |
Bodor JN, Boumber Y, Borghaei H. (2019) Biomarkers for immune checkpoint inhibition in non-small cell lung cancer (NSCLC). Cancer |
Deneka AY, Boumber Y, Beck T, et al. (2019) Tumor-Targeted Drug Conjugates as an Emerging Novel Therapeutic Approach in Small Cell Lung Cancer (SCLC). Cancers. 11 |